Platinum Investment Management LTD Cure Vac N.V. Transaction History

Platinum Investment Management LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$2.94 - $4.34 $378,607 - $558,896	128,778 Added 25.86%	626,684 $1.9 Million
Q4 2023 Feb 13, 2024	BUY	$3.96 - $6.41 $533,118 - $862,952	134,626 Added 37.06%	497,906 $2.1 Million
Q3 2023 Nov 02, 2023	BUY	$6.5 - $10.77 $891,449 - $1.48 Million	137,146 Added 60.65%	363,280 $2.48 Million
Q2 2023 Aug 10, 2023	BUY	$6.69 - $12.25 $1.51 Million - $2.77 Million	226,134 New	226,134 $2.36 Million
Q3 2021 Nov 09, 2021	SELL	$49.26 - $74.5 $1.04 Million - $1.57 Million	-21,132 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$56.91 - $127.53 $1.35 Million - $3.02 Million	-23,668 Reduced 52.83%	21,132 $1.55 Million
Q1 2021 May 13, 2021	BUY	$79.79 - $126.29 $2.25 Million - $3.56 Million	28,177 Added 169.51%	44,800 $4.1 Million
Q4 2020 Feb 12, 2021	SELL	$46.76 - $136.27 $2.46 Million - $7.16 Million	-52,553 Reduced 75.97%	16,623 $1.35 Million
Q3 2020 Nov 13, 2020	BUY	$43.8 - $77.2 $3.03 Million - $5.34 Million	69,176 New	69,176 $3.22 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Platinum Investment Management LTD, based on Form 13F filings with the SEC.

Stay updated on Platinum Investment Management LTD with notifications on news.